Immune checkpoint blockade in pancreatic cancer: trudging through the immune desert

X Li, M Gulati, AC Larson, JC Solheim, M Jain… - Seminars in cancer …, 2022 - Elsevier
Pancreatic cancer (PC) has exceptionally high mortality due to ineffective treatment
strategies. Immunotherapy, which mobilizes the immune system to fight against cancer, has …

KRAS-related proteins in pancreatic cancer

KM Mann, H Ying, J Juan, NA Jenkins… - Pharmacology & …, 2016 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease with a high
mortality rate. Genetic and biochemical studies have shown that RAS signaling mediated by …

Kaempferol Inhibits Pancreatic Cancer Cell Growth and Migration through the Blockade of EGFR-Related Pathway In Vitro

J Lee, JH Kim - PloS one, 2016 - journals.plos.org
Pancreatic cancer is one of the most appalling cancers with a pessimistic prognosis. Despite
many therapies, there has been no improvement of survival rates. In this study, we assessed …

Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells

TL Fitzgerald, K Lertpiriyapong, L Cocco… - Advances in biological …, 2015 - Elsevier
Pancreatic cancer is currently the fourth most common cancer, is increasing in incidence
and soon will be the second leading cause of cancer death in the USA. This is a deadly …

Aptamer-conjugated PLGA nanoparticles for delivery and imaging of cancer therapeutic drugs

M Hashemi, A Shamshiri, M Saeedi, L Tayebi… - Archives of biochemistry …, 2020 - Elsevier
Most problems associated with chemotherapeutic agents involve non-specific cytotoxicity,
low intratumoral accumulation and drug resistance. Targeted drug delivery systems (TDDS) …

[HTML][HTML] CD73's potential as an immunotherapy target in gastrointestinal cancers

JB Harvey, LH Phan, OE Villarreal… - Frontiers in …, 2020 - frontiersin.org
CD73, a cell surface 5′ nucleotidase that generates adenosine, has emerged as an
attractive therapeutic target for reprogramming cancer cells and the tumor microenvironment …

Impacting Pancreatic Cancer Therapy in Heterotypic in Vitro Organoids and in Vivo Tumors with Specificity-Tuned, NIR-Activable Photoimmunonanoconjugates …

G Obaid, S Bano, S Mallidi, M Broekgaarden… - Nano …, 2019 - ACS Publications
Despite untiring efforts to develop therapies for pancreatic ductal adenocarcinoma (PDAC),
survival statistics remain dismal, necessitating distinct approaches. Photodynamic priming …

Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs

A Olatunde, M Nigam, RK Singh, AS Panwar… - Cancer cell …, 2021 - Springer
Cancers are regarded as one of the main causes of death and result in high health burden
worldwide. The management of cancer include chemotherapy, surgery and radiotherapy …

Developing effective combination therapy for pancreatic cancer: An overview

AL Miller, PL Garcia, KJ Yoon - Pharmacological research, 2020 - Elsevier
Pancreatic cancer is a fatal disease. The five-year survival for patients with all stages of this
tumor type is less than 10%, with a majority of patients dying from drug resistant, metastatic …

Recent progress of benzimidazole hybrids for anticancer potential

MJ Akhtar, MS Yar, VK Sharma… - Current Medicinal …, 2020 - ingentaconnect.com
This review presents the detailed account of factors leading to cancer and design strategy
for the synthesis of benzimidazole derivatives as anticancer agents. The recent survey for …